Description
Product Specifications
- Product: Retatrutide 30mg
- Compound / formulation: Retatrutide (LY3437943)
- Labeled quantity / volume: 30mg per vial
- Physical form: White lyophilized powder
- Research focus: Metabolic Research, Glucose Regulation, Appetite & Energy Balance, Incretin Signaling
- Available batch identifiers: Emerald-green cap, batch R30-HOP-0826; clear pink cap, Freedom Diagnostics accession 2610260170
- SKU: HOP-retatrutide-30mg
- Intended classification: Laboratory research only
Independent Laboratory Testing
Emerald green cap — Janoshik Analytical, report #228635 — Batch R30-HOP-0826
- Compound reported: Retatrutide
- Measured content, sample 1: 34.44mg
- Purity, sample 1: 99.846%
- Measured content, sample 2: 34.65mg
- Purity, sample 2: 99.819%
- Test date: September 10, 2026
- View laboratory report
Clear pink cap — Freedom Diagnostics, accession 2610260170
- Compound reported: GLP RT (report identity label)
- Measured content: 34.82mg
- Purity: 99.87%
- Report date: October 27, 2026
- View laboratory report
House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.
The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.
House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.
Scientific Research Background
Retatrutide is being studied because it acts on three hormone receptors involved in metabolism: GIP, GLP-1, and glucagon.
GIP and GLP-1 help regulate the body's response to food, including blood sugar and appetite. Glucagon helps regulate how the body makes energy available, particularly through its effects on the liver.
Researchers are investigating how these three pathways work together and whether targeting them at the same time produces different results than targeting one or two.
Retatrutide remains investigational. Findings from clinical trials do not establish equivalent results for independently sourced research materials.
Compound details
- Research classification: GIP / GLP-1 / glucagon receptor agonist
Clinical Research Observations
1. Why are researchers interested in retatrutide?
Retatrutide acts on three hormone receptors involved in metabolism: GLP-1, GIP, and glucagon.
What researchers found: Clinical studies have reported changes in body weight and metabolic measurements when these pathways are activated together.
Why it matters: Researchers are investigating whether targeting three pathways produces different results than targeting one or two.
2. What have earlier clinical trials found about body weight?
Researchers have studied retatrutide in adults with obesity or overweight and related health conditions.
What researchers found: In a 48-week phase 2 trial involving 338 adults, the highest-dose group experienced an average body-weight reduction of 24.2%, compared with 2.1% in the placebo group.
Why it matters: These results supported larger clinical studies. They do not predict any individual person's outcome.
3. What did the larger phase 3 retatrutide trial discover?
Researchers conducted a larger study to investigate retatrutide in adults with obesity.
What researchers found: In an 80-week trial involving 2,339 participants, average weight reduction reached 25.0% in the highest-dose group, compared with 3.9% for placebo.
Why it matters: Larger trials provide additional evidence about the studied populations and formulations. Their findings do not establish equivalent effects for independently sourced research vials.
4. What safety observations have been reported?
Clinical trials track unwanted effects as well as changes in weight and blood sugar.
What researchers found: Stomach and digestive symptoms, including nausea and vomiting, have been reported. Researchers have also monitored changes in heart rate.
Why it matters: Safety observations are necessary for interpreting clinical trial results and identifying questions for further investigation.
5. What is the overall scientific takeaway?
Retatrutide has demonstrated metabolic effects in controlled human studies.
What researchers found: Published trial results concern specifically manufactured investigational formulations evaluated under defined research protocols.
Why it matters: These findings do not establish the safety, effectiveness, or equivalence to the medicines studied of House of Peptides research vials.
Published Scientific Research
- Jastreboff et al. (2023), Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial, New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2301972
- Jastreboff et al. (2026), Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity, New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2604169
Understanding the Research Findings
Independent laboratory analyses of submitted samples associated with House of Peptides’ Retatrutide 30mg inventory reported identification of retatrutide.
The clinical findings above relate to investigational materials evaluated in Eli Lilly’s studies. Identifying the compound does not establish identical formulation, pharmaceutical quality, safety, or clinical outcomes. Retatrutide remains investigational; House of Peptides’ research product is not FDA-approved or represented as equivalent to clinical-trial materials.
House of Peptides is not affiliated with or endorsed by Eli Lilly and Company.
Research Use Notice
For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.
Reviews
There are no reviews yet.